-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 18, the official website of the State Food and Drug Administration showed that the supplementary application for Linezolid Glucose Injection of Chia Tai Tianqing Pharmaceutical Group was approved and reviewed.
Before that, the product company had a product review
.
According to data from Minet.
com, in 2020, the sales of linezolid glucose injection in China's public medical institutions will exceed 1.
5 billion yuan, with a slight increase of 2.
66% year-on-year in the first half of 2021.
Among them, Pfizer has the largest market share
.
At present, this product has been reviewed by 6 companies, and Zhejiang Pharmaceutical Co.
, Ltd.
Xinchang Pharmaceutical's supplementary application for consistency evaluation is under review and approval; The product is in the review and approval process, and it is deemed to have passed the review after approval
.
Before that, the product company had a product review
.
According to data from Minet.
com, in 2020, the sales of linezolid glucose injection in China's public medical institutions will exceed 1.
5 billion yuan, with a slight increase of 2.
66% year-on-year in the first half of 2021.
Among them, Pfizer has the largest market share
.
At present, this product has been reviewed by 6 companies, and Zhejiang Pharmaceutical Co.
, Ltd.
Xinchang Pharmaceutical's supplementary application for consistency evaluation is under review and approval; The product is in the review and approval process, and it is deemed to have passed the review after approval
.
February 18, 2022 Information release of drug approval documents to be received
Linezolid is a synthetic oxazolidinone antibiotic mainly used to treat infections caused by Gram-positive bacteria that are resistant to other antibiotics.
The original research company is Pfizer
.
The original research company is Pfizer
.
Sales of terminal linezolid glucose injection in Chinese public medical institutions in recent years (unit: 100 million yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
According to data from Minet.
com, in 2020, the sales of terminal linezolid glucose injection in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
5 billion yuan, and the first half of 2021 was year-on-year.
an increase of 2.
66%
.
Among them, Pfizer has the largest market share, exceeding 50%; Jiangsu Hansoh Pharmaceutical and Chia Tai Tianqing Pharmaceutical Group ranked second and third respectively
.
com, in 2020, the sales of terminal linezolid glucose injection in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
5 billion yuan, and the first half of 2021 was year-on-year.
an increase of 2.
66%
.
Among them, Pfizer has the largest market share, exceeding 50%; Jiangsu Hansoh Pharmaceutical and Chia Tai Tianqing Pharmaceutical Group ranked second and third respectively
.
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
At present, 12 companies have production approvals for Linezolid Glucose Injection, of which 6 companies have reviewed them, and 5 companies including Sichuan Meida Konkale Pharmaceutical, Hunan Kelun Pharmaceutical, and Jiangsu Zhengda Fenghai Pharmaceutical have obtained supplementary applications.
After being criticized, Shijiazhuang No.
4 medicines were approved for production of 4 types of imitations, which is regarded as a review
.
After being criticized, Shijiazhuang No.
4 medicines were approved for production of 4 types of imitations, which is regarded as a review
.
In addition, the supplementary application for consistency evaluation of Xinchang Pharmaceutical Factory of Zhejiang Pharmaceutical Co.
, Ltd.
is under review and approval; Sichuan Kelun Pharmaceutical, Yangzijiang Pharmaceutical Group Shanghai Haini Pharmaceutical, Guangzhou Green Cross Pharmaceutical, Chongqing Shenghuaxi Pharmaceutical, etc.
6 companies reported production of 4 types of imitations in the review and approval process, and they were deemed to have passed the review after approval
.
, Ltd.
is under review and approval; Sichuan Kelun Pharmaceutical, Yangzijiang Pharmaceutical Group Shanghai Haini Pharmaceutical, Guangzhou Green Cross Pharmaceutical, Chongqing Shenghuaxi Pharmaceutical, etc.
6 companies reported production of 4 types of imitations in the review and approval process, and they were deemed to have passed the review after approval
.
It is worth noting that Linezolid Glucose Injection is the fifth batch of domestically sourced varieties.
Jiangsu Hansoh Pharmaceutical, Jiangsu Zhengda Fenghai Pharmaceutical, and Hunan Kelun Pharmaceutical won the bid.
In the future, the market pattern of this product will change
.
Jiangsu Hansoh Pharmaceutical, Jiangsu Zhengda Fenghai Pharmaceutical, and Hunan Kelun Pharmaceutical won the bid.
In the future, the market pattern of this product will change
.
On February 18, the official website of the State Food and Drug Administration showed that the supplementary application for Linezolid Glucose Injection of Chia Tai Tianqing Pharmaceutical Group was approved and reviewed.
Before that, the product company had a product review
.
According to data from Minet.
com, in 2020, the sales of linezolid glucose injection in China's public medical institutions will exceed 1.
5 billion yuan, with a slight increase of 2.
66% year-on-year in the first half of 2021.
Among them, Pfizer has the largest market share
.
At present, this product has been reviewed by 6 companies, and Zhejiang Pharmaceutical Co.
, Ltd.
Xinchang Pharmaceutical's supplementary application for consistency evaluation is under review and approval; The product is in the review and approval process, and it is deemed to have passed the review after approval
.
Before that, the product company had a product review
.
According to data from Minet.
com, in 2020, the sales of linezolid glucose injection in China's public medical institutions will exceed 1.
5 billion yuan, with a slight increase of 2.
66% year-on-year in the first half of 2021.
Among them, Pfizer has the largest market share
.
At present, this product has been reviewed by 6 companies, and Zhejiang Pharmaceutical Co.
, Ltd.
Xinchang Pharmaceutical's supplementary application for consistency evaluation is under review and approval; The product is in the review and approval process, and it is deemed to have passed the review after approval
.
February 18, 2022 Information release of drug approval documents to be received
Linezolid is a synthetic oxazolidinone antibiotic mainly used to treat infections caused by Gram-positive bacteria that are resistant to other antibiotics.
The original research company is Pfizer
.
The original research company is Pfizer
.
Sales of terminal linezolid glucose injection in Chinese public medical institutions in recent years (unit: 100 million yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
According to data from Minet.
com, in 2020, the sales of terminal linezolid glucose injection in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
5 billion yuan, and the first half of 2021 was year-on-year.
an increase of 2.
66%
.
Among them, Pfizer has the largest market share, exceeding 50%; Jiangsu Hansoh Pharmaceutical and Chia Tai Tianqing Pharmaceutical Group ranked second and third respectively
.
com, in 2020, the sales of terminal linezolid glucose injection in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
5 billion yuan, and the first half of 2021 was year-on-year.
an increase of 2.
66%
.
Among them, Pfizer has the largest market share, exceeding 50%; Jiangsu Hansoh Pharmaceutical and Chia Tai Tianqing Pharmaceutical Group ranked second and third respectively
.
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
At present, 12 companies have production approvals for Linezolid Glucose Injection, of which 6 companies have reviewed them, and 5 companies including Sichuan Meida Konkale Pharmaceutical, Hunan Kelun Pharmaceutical, and Jiangsu Zhengda Fenghai Pharmaceutical have obtained supplementary applications.
After being criticized, Shijiazhuang No.
4 medicines were approved for production of 4 types of imitations, which is regarded as a review
.
After being criticized, Shijiazhuang No.
4 medicines were approved for production of 4 types of imitations, which is regarded as a review
.
In addition, the supplementary application for consistency evaluation of Xinchang Pharmaceutical Factory of Zhejiang Pharmaceutical Co.
, Ltd.
is under review and approval; Sichuan Kelun Pharmaceutical, Yangzijiang Pharmaceutical Group Shanghai Haini Pharmaceutical, Guangzhou Green Cross Pharmaceutical, Chongqing Shenghuaxi Pharmaceutical, etc.
6 companies reported production of 4 types of imitations in the review and approval process, and they were deemed to have passed the review after approval
.
, Ltd.
is under review and approval; Sichuan Kelun Pharmaceutical, Yangzijiang Pharmaceutical Group Shanghai Haini Pharmaceutical, Guangzhou Green Cross Pharmaceutical, Chongqing Shenghuaxi Pharmaceutical, etc.
6 companies reported production of 4 types of imitations in the review and approval process, and they were deemed to have passed the review after approval
.
It is worth noting that Linezolid Glucose Injection is the fifth batch of domestically sourced varieties.
Jiangsu Hansoh Pharmaceutical, Jiangsu Zhengda Fenghai Pharmaceutical, and Hunan Kelun Pharmaceutical won the bid.
In the future, the market pattern of this product will change
.
Jiangsu Hansoh Pharmaceutical, Jiangsu Zhengda Fenghai Pharmaceutical, and Hunan Kelun Pharmaceutical won the bid.
In the future, the market pattern of this product will change
.
On February 18, the official website of the State Food and Drug Administration showed that the supplementary application for Linezolid Glucose Injection of Chia Tai Tianqing Pharmaceutical Group was approved and reviewed.
Before that, the product company had a product review
.
According to data from Minet.
com, in 2020, the sales of linezolid glucose injection in China's public medical institutions will exceed 1.
5 billion yuan, with a slight increase of 2.
66% year-on-year in the first half of 2021.
Among them, Pfizer has the largest market share
.
At present, this product has been reviewed by 6 companies, and Zhejiang Pharmaceutical Co.
, Ltd.
Xinchang Pharmaceutical's supplementary application for consistency evaluation is under review and approval; The product is in the review and approval process, and it is deemed to have passed the review after approval
.
Before that, the product company had a product review
.
According to data from Minet.
com, in 2020, the sales of linezolid glucose injection in China's public medical institutions will exceed 1.
5 billion yuan, with a slight increase of 2.
66% year-on-year in the first half of 2021.
Among them, Pfizer has the largest market share
.
At present, this product has been reviewed by 6 companies, and Zhejiang Pharmaceutical Co.
, Ltd.
Xinchang Pharmaceutical's supplementary application for consistency evaluation is under review and approval; The product is in the review and approval process, and it is deemed to have passed the review after approval
.
February 18, 2022 Information release of drug approval documents to be received
Linezolid is a synthetic oxazolidinone antibiotic mainly used to treat infections caused by Gram-positive bacteria that are resistant to other antibiotics.
The original research company is Pfizer
.
The original research company is Pfizer
.
Sales of terminal linezolid glucose injection in Chinese public medical institutions in recent years (unit: 100 million yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
According to data from Minet.
com, in 2020, the sales of terminal linezolid glucose injection in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
5 billion yuan, and the first half of 2021 was year-on-year.
an increase of 2.
66%
.
Among them, Pfizer has the largest market share, exceeding 50%; Jiangsu Hansoh Pharmaceutical and Chia Tai Tianqing Pharmaceutical Group ranked second and third respectively
.
hospital hospital hospitalcom, in 2020, the sales of terminal linezolid glucose injection in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
5 billion yuan, and the first half of 2021 was year-on-year.
an increase of 2.
66%
.
Among them, Pfizer has the largest market share, exceeding 50%; Jiangsu Hansoh Pharmaceutical and Chia Tai Tianqing Pharmaceutical Group ranked second and third respectively
.
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
At present, 12 companies have production approvals for Linezolid Glucose Injection, of which 6 companies have reviewed them, and 5 companies including Sichuan Meida Konkale Pharmaceutical, Hunan Kelun Pharmaceutical, and Jiangsu Zhengda Fenghai Pharmaceutical have obtained supplementary applications.
After being criticized, Shijiazhuang No.
4 medicines were approved for production of 4 types of imitations, which is regarded as a review
.
After being criticized, Shijiazhuang No.
4 medicines were approved for production of 4 types of imitations, which is regarded as a review
.
In addition, the supplementary application for consistency evaluation of Xinchang Pharmaceutical Factory of Zhejiang Pharmaceutical Co.
, Ltd.
is under review and approval; Sichuan Kelun Pharmaceutical, Yangzijiang Pharmaceutical Group Shanghai Haini Pharmaceutical, Guangzhou Green Cross Pharmaceutical, Chongqing Shenghuaxi Pharmaceutical, etc.
6 companies reported production of 4 types of imitations in the review and approval process, and they were deemed to have passed the review after approval
.
Pharmaceutical pharmaceutical pharmaceutical enterprise enterprise enterprise, Ltd.
is under review and approval; Sichuan Kelun Pharmaceutical, Yangzijiang Pharmaceutical Group Shanghai Haini Pharmaceutical, Guangzhou Green Cross Pharmaceutical, Chongqing Shenghuaxi Pharmaceutical, etc.
6 companies reported production of 4 types of imitations in the review and approval process, and they were deemed to have passed the review after approval
.
It is worth noting that Linezolid Glucose Injection is the fifth batch of domestically sourced varieties.
Jiangsu Hansoh Pharmaceutical, Jiangsu Zhengda Fenghai Pharmaceutical, and Hunan Kelun Pharmaceutical won the bid.
In the future, the market pattern of this product will change
.
Jiangsu Hansoh Pharmaceutical, Jiangsu Zhengda Fenghai Pharmaceutical, and Hunan Kelun Pharmaceutical won the bid.
In the future, the market pattern of this product will change
.
